238 related articles for article (PubMed ID: 31751580)
1. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
2. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
3. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
[TBL] [Abstract][Full Text] [Related]
4. Neonatal Murine Engineered Cardiac Tissue Toxicology Model: Impact of Metallothionein Overexpression on Cadmium-Induced Injury.
Yu H; Ye F; Yuan F; Cai L; Ji H; Keller BB
Toxicol Sci; 2018 Oct; 165(2):499-511. PubMed ID: 29982767
[TBL] [Abstract][Full Text] [Related]
5. Zinc protects against cadmium-induced toxicity in neonatal murine engineered cardiac tissues via metallothionein-dependent and independent mechanisms.
Yu HT; Zhen J; Xu JX; Cai L; Leng JY; Ji HL; Keller BB
Acta Pharmacol Sin; 2020 May; 41(5):638-649. PubMed ID: 31768045
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice.
Bosman M; Krüger DN; Favere K; De Meyer GRY; Franssen C; Van Craenenbroeck EM; Guns PJ
PLoS One; 2023; 18(11):e0294848. PubMed ID: 38015959
[TBL] [Abstract][Full Text] [Related]
7. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein prevents doxorubicin cardiac toxicity by indirectly regulating the uncoupling proteins 2.
Jing L; Yang M; Li Y; Yu Y; Liang B; Cao L; Zhou X; Peng S; Sun Z
Food Chem Toxicol; 2017 Dec; 110():204-213. PubMed ID: 29061315
[TBL] [Abstract][Full Text] [Related]
9. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
[TBL] [Abstract][Full Text] [Related]
10. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
[TBL] [Abstract][Full Text] [Related]
11. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
Bures J; Jirkovska A; Sestak V; Jansova H; Karabanovich G; Roh J; Sterba M; Simunek T; Kovarikova P
Toxicology; 2017 Dec; 392():1-10. PubMed ID: 28941780
[TBL] [Abstract][Full Text] [Related]
12. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats.
Rao VA; Zhang J; Klein SR; Espandiari P; Knapton A; Dickey JS; Herman E; Shacter EB
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1125-34. PubMed ID: 21373894
[TBL] [Abstract][Full Text] [Related]
13. JAK2/STAT3 Pathway Mediates Protection of Metallothionein Against Doxorubicin-Induced Cytotoxicity in Mouse Cardiomyocytes.
Rong J; Li L; Jing L; Fang H; Peng S
Int J Toxicol; 2016 May; 35(3):317-26. PubMed ID: 26526549
[TBL] [Abstract][Full Text] [Related]
14. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
Yu X; Ruan Y; Shen T; Qiu Q; Yan M; Sun S; Dou L; Huang X; Wang Q; Zhang X; Man Y; Tang W; Jin Z; Li J
Biomed Res Int; 2020; 2020():5107193. PubMed ID: 32190669
[TBL] [Abstract][Full Text] [Related]
16. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice.
Fu Z; Guo J; Jing L; Li R; Zhang T; Peng S
Toxicol In Vitro; 2010 Sep; 24(6):1584-91. PubMed ID: 20600803
[TBL] [Abstract][Full Text] [Related]
17. Zinc-induced metallothionein overexpression prevents doxorubicin toxicity in cardiomyocytes by regulating the peroxiredoxins.
Jing L; Li L; Zhao J; Zhao J; Sun Z; Peng S
Xenobiotica; 2016 Aug; 46(8):715-25. PubMed ID: 26599915
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
[TBL] [Abstract][Full Text] [Related]
19. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]